Healthcare Regulation (HIPAA)

New appointments bring deep legal and pharma expertise to Canada's Patented Medicine Prices Review Board, signaling a pivotal moment under new 2026 guidelines.

A new bill named for a man failed by the system aims to modernize medical psilocybin access. But can it overcome bureaucratic inertia and position Canada as a leader?

A new partnership between HCPro and ZHealth aims to solve the costly, error-prone challenge of specialty coding in radiology and cardiology. Here’s why.

When a long-term disability claim is denied, the clock starts ticking. Here’s how to understand the insurer's playbook and the legal maze you must navigate.

Canada's sweeping new bail and sentencing law promises safer streets, but critics warn it could strain the justice system and erode fundamental rights.

As Colorado's special education needs grow, private schools like The ACES report success. But what does this model reveal about the broader system?

With the EU's Cyber Resilience Act's 24-hour reporting deadline looming, a new class of AI-powered platforms is emerging to manage this unprecedented compliance risk.

Beyond a simple rebrand, CTM's new integrations and strategic hires reveal a deeper play to solve the market's biggest data disconnect for modern business.

A new partnership between IS3WARE and Privacy Horizon signals a pivotal shift in how our most sensitive sectors will defend against digital and regulatory threats.

A guidance cut at Sanuwave reveals a deeper crisis in wound care, driven by CMS policy shifts that are fueling a disruptive secondary equipment market.

A new Supreme Court ruling just upended risk for freight brokers. RoxStart AI's new platform offers a timely, tech-driven defense for the industry's backbone.

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

A new AI platform promises to slash drug development red tape. But can it overcome the industry’s deep-rooted challenges of privacy, trust, and integration?

A new AI tool is shifting post-acute care from relationship-based referrals to data-driven strategy by analyzing entire physician groups, not just doctors.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

The online therapy market is booming, attracting institutional capital. We dissect the growth drivers, regulatory risks, and evolving business models.

With air quality plummeting, a new wellness market is booming. We investigate the science and business behind lung health supplements for wildfire season.